India's $1B nutraceutical market hits trust test as HUL-OZiva deal signals consolidation

Direct-to-consumer nutraceutical category at $1B faces credibility crisis from influencer misinformation and weak scientific validation, even as FSSAI formalises rules. HUL's ₹824 cr OZiva buyout for 49% stake marks institutional consolidation. Sector growing 10.5-13% YoY in FY26, with $23-85B potential by 2034 against under-2 products per person vs Japan's 350.

Direct-to-consumer nutraceutical category at $1B faces credibility crisis from influencer misinformation and weak scientific validation, even as FSSAI formalise

The Hindu BusinessLine · 6/4/2026, 1:06:50 PM · Ask about this →

Indian Nutraceutical Industry + Dr Reddy's-Nestlé Health Sciences + FSSAI + Hindustan Unilever + Maharashtra FDA + Oziva + Zantus Life Sciences +